AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03239522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK1278863 solution for IV infusion
Description: It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
Study NCT03239522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK1278863 oral solution
Description: It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
Study NCT03239522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat 6 mg oral tablet
Description: It is a 9.0 millimeter (mm) round, white film coated tablet.
Study NCT02519322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02519322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02519322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02519322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV
Study NCT02519322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT03375593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone 5Mg/Acetaminophen 500Mg Tab
Description: tablet
Study NCT03375593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Tab
Description: tablet
Study NCT03375593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg tab
Description: tablet
Study NCT03145714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintainance of anesthesia with Intravenous Propofol infusion
Description: The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
Study NCT03145714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintainance of anesthesia with Intravenous Dexmedetomidine
Description: The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
Study NCT00720096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal Doxorubicin 40 mg/m2 q 28 days
Study NCT00720096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 1. Topotecan (daily x 5 days of a 21 day cycle)~2. Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)
Study NCT01229852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSF-rTMS
Description: Effective Transcranial Magnetic Stimulation
Study NCT01444703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: licorice solution
Description: licorice (0.5 g)
Study NCT01444703 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar solution
Description: sugar (5 g).
Study NCT02502253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grape seed polyphenolic extract, resveratrol
Description: Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.
Study NCT00055978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally. 400mg twice daily for 6 months.
Study NCT00055978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT04461665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: vitamin D supplement 10 μg daily for 2 months
Study NCT02503943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide and Mitiglinide
Description: Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)
Study NCT02503943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Mitiglinide
Description: Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)
Study NCT02503943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: Mitiglinide (50mg, 3/d)
Study NCT01781286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Protein
Description: 250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
Study NCT01781286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Protein
Description: 5% Protein; 50% Carbohydrates; 45% Fat
Study NCT00939653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
Study NCT00939653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
Study NCT00939653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
Study NCT00939653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000 x 2 days.
Study NCT00939653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients >3 years of age
Study NCT02511405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111 + bevacizumab
Description: VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
Study NCT02511405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
Study NCT06447883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Description: The LMP included 12 treatment modules which was administered by the occupational therapist with a national occupational therapist license and a certification from the USC Lifestyle Redesign® course in 2001. The experimental group engaged in 24 weekly group sessions, each lasting approximately 2 hours. Each session started with stretching, followed by knowledge sharing, group discussion, and activities participation which aligned with the session's themes and discussion topics. The four strategies, including didactic presentation, peer exchange, direct experience, and personal exploration, were employed to deliver the treatment module content. Following these strategies, the primary researcher emphasized the connection between participants' personal meanings, individual contexts, and occupations. Afterward, participants were encouraged to formulate a personalized action plan and integrate what they had learnt into their daily routine.
Study NCT02922868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoSheath CST-5000 Scope
Description: Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
Study NCT02922868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Olympus Visera Elite OTV-S190 Scope
Description: Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
Study NCT00766688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment
Study NCT00766688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment
Study NCT03756857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Afterload Transfer
Description: Embryo transfer is done by using afterload transfer method
Study NCT03756857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trial followed by transfer
Description: Embryo transfer is done by using afterload transfer method
Study NCT03417544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATEZOLIZUMAB
Description: (IV) every 3 weeks
Study NCT03417544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERTUZUMAB
Description: Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
Study NCT03417544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRASTUZUMAB
Description: Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks
Study NCT01375322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine+Benazepril
Description: Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
Study NCT01375322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan+Hydrochlorothiazide
Description: Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
Study NCT03329027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Capsule
Description: Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
Study NCT03329027 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham capsule
Description: Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
Study NCT04223440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI on both shoulder
Study NCT04223440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI on both shoulder
Study NCT04223440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasonographic explorations
Description: ultrasound and elastography explorations on both shoulder
Study NCT04223440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasonographic explorations
Description: ultrasound and elastography explorations on both shoulder
Study NCT04480398 — intervention group
Intervention type: DRUG
Intervention: Guduchi Ghan Vati
Description: Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
Study NCT00497796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maribavir
Description: 100mg twice a day for 14 weeks.
Study NCT00497796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ganciclovir
Description: 1000mg three times per day for 14 weeks.
Study NCT01074554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic Regimen
Description: Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
Study NCT01074554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Regimen
Description: lactose control tablets; one for each antibiotic with equivalent pills
Study NCT03970564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neck ultrasound guide lymph node sampling
Description: Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
Study NCT01976130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Study NCT01611389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonging atrioventricular (AV) delay.
Description: Prolonging atrioventricular (AV) delay to maximum 350 ms.
Study NCT01611389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard atrioventricular (AV) delay.
Description: Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
Study NCT04418388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK-1801
Description: Administered orally
Study NCT02780336 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
Study NCT00220337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
Study NCT01624376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DLX105
Description: 10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
Study NCT01624376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections are administered over the treatment period of 4 weeks.
Study NCT03393650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Placebo group
Description: 1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo
Study NCT03393650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Protein group
Description: 1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
Study NCT03661528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: andexanet alfa
Description: Andexanet alfa is a recombinant version of human FXa
Study NCT03661528 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Usual Care
Description: Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
Study NCT04860219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: 7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR
Study NCT03889756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Description: The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.
Study NCT03889756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam infusion
Description: The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
Study NCT02566824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural & Skills Training
Description: This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q\&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
Study NCT02566824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Group Therapy
Description: This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
Study NCT02566824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual - community resources
Description: The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
Study NCT02566824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate or amphetamine product
Description: Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
Study NCT02566824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate or amphetamine product
Description: Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
Study NCT04452734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: PRP was prepared by withdrawing 8-10 ml of patients own blood (IV from antecubiodal area and collected in a vacuum tube coated with anticoagulant (Na citrate). For activation 1 ml of calcium chloride was added to Platelet Rich Plasma. This layer of approximately 2 ml of PRP was then taken into the residual bone cavity along with gel sponge to stimulate regeneration in wound healing after surgical extraction of mandibular third molar tooth followed by sutures
Study NCT04452734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Extraction
Description: Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.
Study NCT04452734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Extraction
Description: Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.
Study NCT00643578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
Study NCT00643578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
Study NCT00643578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Powder Inhaler (Twisthaler)
Description: subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
Study NCT04540640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney perfusion pump
Description: The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
Study NCT03236181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SFA
Description: High saturated fatty acid/SFA oil source
Study NCT03236181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MUFA
Description: High monounsaturated fatty acid/MUFA oil source
Study NCT03236181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PUFA
Description: High polyunsaturated fatty acid (linoleic)/PUFA oil source
Study NCT03236181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LCn3
Description: High polyunsaturated fatty acid (omega-3)/LCn3 oil source
Study NCT03683407 — intervention group
Intervention type: OTHER
Intervention: Next-Genernation Sequence
Description: Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
Study NCT00984295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: A single 0.5 mL subcutaneous injection at Day 0